Free cash flow
Alnylam Pharmaceuticals Free cash flow decreased by 65.3% to $48.67M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 137.6%, from -$129.28M to $48.67M. Over 3 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a -13.5% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong operational efficiency and the ability to self-fund future innovation or return capital to shareholders, while a decrease may indicate heavy capital expenditure cycles or declining operational profitability.
Detailed definition
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Peer comparison
High-growth semiconductor and AI infrastructure peers typically prioritize reinvestment, so free cash flow margins are often compared against R&D intensity and capital expenditure requirements of industry rivals.
free_cash_flowHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$133.10M | -$160.10M | -$172.03M | -$189.05M | -$138.87M | -$131.79M | -$153.61M | -$180.37M | -$74.91M | $342.32M | -$94.49M | $116.14M | $39.52M | -$103.76M | -$129.28M | $141.44M | $312.97M | $140.26M | $48.67M |
| QoQ Change | — | -20.3% | -7.5% | -9.9% | +26.5% | +5.1% | -16.6% | -17.4% | +58.5% | +557.0% | -127.6% | +222.9% | -66.0% | -362.6% | -24.6% | +209.4% | +121.3% | -55.2% | -65.3% |
| YoY Change | — | — | — | — | -4.3% | +17.7% | +10.7% | +4.6% | +46.1% | +359.7% | +47.6% | +255.0% | -88.5% | — | -36.8% | +21.8% | +692.0% | +235.2% | +137.6% |
Free cash flow at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's free cash flow?
- Alnylam Pharmaceuticals (ALNY) reported free cash flow of $48.67M in Q1 2026.
- How has Alnylam Pharmaceuticals's free cash flow changed year-over-year?
- Alnylam Pharmaceuticals's free cash flow increased by 137.6% year-over-year, from -$129.28M to $48.67M.
- What is the long-term trend for Alnylam Pharmaceuticals's free cash flow?
- Over 3 years (2021 to 2025), Alnylam Pharmaceuticals's free cash flow has grown at a -13.5% compound annual growth rate (CAGR), from -$718.07M to $465.38M.
- What does free cash flow mean?
- The cash a company has left over after paying for its operating expenses and capital investments.